fig7

Figure 7. Addressing the Therapeutic Gap in Moderate Psoriasis with MSC-sEVs. Current treatments leave patients with moderate psoriasis undertreated - topicals and phototherapy are inadequate, while biologics are restricted to severe disease. Topically applied MSC-EVs offer a novel, localized, non-immunosuppressive therapeutic option that bridges this gap by delivering targeted immunomodulation directly at the skin surface. (Figure was created with AI-assisted technologies). MSC-sEVs: Mesenchymal stem cell-derived small extracellular vesicles; MSC-EVs: mesenchymal stem cell-derived extracellular vesicles.